Compare VF Corp (VFC) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VF Corp vs Zoetis Inc — how do they compare? VF Corp trades at $14.66 (market cap $5.81B), while Zoetis Inc trades at $72.6 (market cap $31.14B). The key difference: Zoetis Inc is far larger — about 5.4× VF Corp's market cap, and Zoetis Inc pays the higher dividend (2.81%). Which is the better fit depends on your goals.
| VFC | ZTS | |
|---|---|---|
Market Cap | $5.81B | $31.14B |
Sector | Consumer Cyclical | Health |
52-Week High | $21.55 | $156.76 |
52-Week Low | $12.21 | $71.91 |
Enterprise Value | $10.09B | $38.70B |
Dividend Yield | 2.44% | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VFC trades at $14.70, down 1.34% over 24 hours, with a bearish technical signal and neutral oscillators. Recent earnings showed a Q2 2026 miss with a loss of $0.27 per share versus a $0.22 loss expected, though Q4 2025 beat expectations. Revenue declined to $9.50 billion in 2025, with a net loss of $189.72 million, while the company maintains a gross margin of 54.97%. Deleveraging progress continues, but Vans brand performance remains a headwind.
The outlook is mixed; analyst consensus is a 'Hold' with a $17.44 price target, implying potential upside. Risks include persistent Vans weakness, macroeconomic pressures, and competitive dynamics. Positive catalysts include raised fiscal 2027 revenue guidance and margin improvements, but execution on brand turnaround is critical for stock appreciation.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
